Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacytidine Conditioning for Allo-HSCT in MDS
NCT06471946Phase 2Recruiting
- Start
- Oct 2024
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in myelodysplastic syndrome (MDS). Primary endpoint: Overall Survival at 3 years. Started Oct 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06471946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471946.